DE602006006068D1 - Verwendung von botulintoxin zur verbesserung der magenentleerung und/oder behandlung von gerd - Google Patents

Verwendung von botulintoxin zur verbesserung der magenentleerung und/oder behandlung von gerd

Info

Publication number
DE602006006068D1
DE602006006068D1 DE602006006068T DE602006006068T DE602006006068D1 DE 602006006068 D1 DE602006006068 D1 DE 602006006068D1 DE 602006006068 T DE602006006068 T DE 602006006068T DE 602006006068 T DE602006006068 T DE 602006006068T DE 602006006068 D1 DE602006006068 D1 DE 602006006068D1
Authority
DE
Germany
Prior art keywords
gerd
botulintoxin
diagnosis
treatment
improve
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006006068T
Other languages
English (en)
Inventor
Sheena K Aurora
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of DE602006006068D1 publication Critical patent/DE602006006068D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE602006006068T 2005-08-24 2006-08-18 Verwendung von botulintoxin zur verbesserung der magenentleerung und/oder behandlung von gerd Active DE602006006068D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/211,311 US7910116B2 (en) 2005-08-24 2005-08-24 Use of a botulinum toxin to improve gastric emptying and/or to treat GERD
PCT/US2006/032295 WO2007024672A1 (en) 2005-08-24 2006-08-18 Use of a botulinum toxin to improve gastric emptying and/or to treat gerd

Publications (1)

Publication Number Publication Date
DE602006006068D1 true DE602006006068D1 (de) 2009-05-14

Family

ID=37496459

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006006068T Active DE602006006068D1 (de) 2005-08-24 2006-08-18 Verwendung von botulintoxin zur verbesserung der magenentleerung und/oder behandlung von gerd

Country Status (6)

Country Link
US (1) US7910116B2 (de)
EP (1) EP1917032B1 (de)
AT (1) ATE427118T1 (de)
DE (1) DE602006006068D1 (de)
ES (1) ES2322872T3 (de)
WO (1) WO2007024672A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130071466A1 (en) * 2001-08-13 2013-03-21 Lipella Pharmaceuticals Inc. Methods and compositions for treating gastric disorders
US20150037402A1 (en) * 2001-08-13 2015-02-05 Lipella Pharmaceuticals, Inc. Methods and Compositions for Treating Gastric Disorders
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US20080092910A1 (en) * 2006-10-18 2008-04-24 Allergan, Inc. Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US8617571B2 (en) 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
US8357081B2 (en) 2008-12-05 2013-01-22 Onciomed, Inc. Method and apparatus for gastric restriction of the stomach to treat obesity
US8911346B2 (en) * 2008-12-05 2014-12-16 Onclomed, Inc. Gastric restriction devices with fillable chambers and ablation means for treating obesity
US20100249822A1 (en) * 2009-03-31 2010-09-30 Raj Nihalani Method and apparatus for treating obesity and controlling weight gain using adjustable intragastric devices
US8100932B2 (en) 2009-03-31 2012-01-24 Onciomed, Inc. Method and apparatus for treating obesity and controlling weight gain using self-expanding intragastric devices
US20110118650A1 (en) * 2009-11-18 2011-05-19 Anteromed, Inc. Method and apparatus for treating obesity and controlling weight gain and absorption of glucose in mammals
WO2013009625A1 (en) 2011-07-08 2013-01-17 Allergan, Inc. Method for treatment of autonomic nervous system disorders
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
AU2014340137B2 (en) 2013-10-22 2020-02-13 Lipella Pharmaceuticals Inc. Delivery of agents using metastable liposomes
US9457011B2 (en) * 2014-02-25 2016-10-04 Muslim D. Shahid Compositions and methods for the treatment of acid-related gastrointestinal disorders containing a dithiolane compound and a gastric acid secretion inhibitor

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US5427291A (en) 1993-09-21 1995-06-27 Smith; David S. Ski carrier and method employing same
EP1147776B1 (de) 1993-12-28 2010-12-15 Allergan, Inc. Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
ES2238969T3 (es) * 1994-05-09 2005-09-16 William J. Binder Neurotoxinas presinapticas para el tratamiento de cefaleas migrañosas.
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
DE69833059T3 (de) 1997-07-15 2014-12-18 The Regents Of The University Of Colorado, A Body Corporate Verwendung von Botulinumtoxin zur Behandlung von Harninkontinenz
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US6358917B1 (en) * 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6143306A (en) 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6358513B1 (en) 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6328977B1 (en) 2000-02-22 2001-12-11 Allergan Sales, Inc. Method for treating hyperparathyroidism
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6306403B1 (en) 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US7737109B2 (en) 2000-08-11 2010-06-15 Temple University Of The Commonwealth System Of Higher Education Obesity controlling method
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US6787517B1 (en) * 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
US6623742B2 (en) 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
US7238357B2 (en) * 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
US6838434B2 (en) 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US7897147B2 (en) 2004-10-20 2011-03-01 Allergan, Inc. Treatment of premenstrual disorders

Also Published As

Publication number Publication date
WO2007024672A1 (en) 2007-03-01
EP1917032B1 (de) 2009-04-01
US7910116B2 (en) 2011-03-22
US20070048334A1 (en) 2007-03-01
ATE427118T1 (de) 2009-04-15
ES2322872T3 (es) 2009-06-30
EP1917032A1 (de) 2008-05-07

Similar Documents

Publication Publication Date Title
DE602006006068D1 (de) Verwendung von botulintoxin zur verbesserung der magenentleerung und/oder behandlung von gerd
MX2019012818A (es) Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos.
MX2018009539A (es) Uso de comunidades microbianas para la salud humana y animal.
EA201000603A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
EA201490695A1 (ru) Слитые белки для лечения нарушений метаболизма
AR065033A1 (es) Metodos para prevenir y tratar trastornos neurodegenerativos
MX2012000034A (es) Metodos para el tratamiento o la prevencion de la fatiga.
EA201370208A1 (ru) Формы рифаксимина и их применение
SG170775A1 (en) 2 -aminopyridine analogs as glucokinase activators
EA201390739A1 (ru) Способ лечения fgf21-ассоциированных расстройств
ATE521608T1 (de) Glucokinaseaktivatoren
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
MX2010006823A (es) Metodos para el tratamiento de la gota.
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
UA109658C2 (xx) Антитіло проти cgrp
EA201490697A1 (ru) Белки с двойной функцией для лечения метаболических расстройств
ATE480255T1 (de) Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
EA201170349A1 (ru) Модуляторы mif
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
MY194587A (en) Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
UA90048C2 (ru) Кондиционированная композиция и способ ее получения
JO2576B1 (en) Antibodies
TW200740804A (en) Glucokinase activators
MX2015002289A (es) Anticuerpos humanos para gfr alfa 3 y métodos para su uso.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition